Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use Misoprostol to Optimize Prevention of Cervical Cancer
Sponsor: University of Alabama at Birmingham
Summary
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Official title: Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial
Key Details
Gender
FEMALE
Age Range
25 Years - Any
Study Type
INTERVENTIONAL
Enrollment
420
Start Date
2025-02-25
Completion Date
2027-11-04
Last Updated
2025-10-01
Healthy Volunteers
Yes
Conditions
Interventions
Placebo
Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Misoprostol
Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Locations (1)
Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé
Yaoundé, Center Region, Cameroon